Carmat, pioneering solutions to revolutionise the healthcare industry

A long-term solution to tackle end-stage heart failure

Chronic heart failure is a progressive disease that affects more than 20 million people in Europe and the United States. Hundreds of thousands of these patients suffer from end-stage heart failure.(1,2)

Heat failure occurs when the pump function of someone’s heart is weakened. It primarily affects the left chamber of the heart, then the right chamber leading to biventricular failure. At this stage, vital organs such as the brain, liver and kidneys do not receive enough nutrients and oxygen to function properly. The main symptoms of the disease include fatigue, shortness of breath – (even at rest), and fluid retention.

Carmat aims to provide a long-term solution to treat end-stage biventricular heart failure, rated as Class IV under the NYHA system (3), for which a heart transplant is still the only truly effective alternative treatment.

(1)Stehlik J. et al. The Registry of the International Society for Heart and Lung Transplantation: 29th Official Adult Heart Transplant Report—2012 J Heart Lung Transplant October 2012 Volume 31, Issue 10, Pages 1052–1064

(2)Miller L. W. Is Left Ventricular Assist Device Therapy Underutilized in the Treatment of Heart Failure? Circulation 2011;123;1552-1558

(3)The New York Heart Association (NYHA)


+ 100,000

patients under 70 years old suffer from end-stage biventricular heart failure every year.(1,2)


of patients diagnosed with heart failure survive 5 years after being diagnosed.(1,2)


heart transplants

Our vision

Carmat will become the number one option to transplant. 

Our mission

Carmat will provide Cardiologists with innovative technologies that save lives and improve the Quality of Life for Patients with advanced heart failure thanks to the engagement of its Employees and the support of its Shareholders.

Discover the heart Carmat
Our Core Values

Every day each Carmat associate focuses on what really matters to provide patients and physicians with an alternative treatment to end-stage heart failure.


We promote a results-driven culture that praises to be proactive, solve problem while maintaining the highest quality standards.

We approach challenges positively as well as encourage our stakeholders to welcome and share opinions to generate innovative medical products.


We foster an agile environment that allows us to adapt rapidly in order to better support our patients and physicians and seize existing business opportunities.


At Carmat we promote integrity and have created an ethical environment where all our stakeholders have an open and transparent communication that sustains our performance.

Discover the heart Carmat

Carmat governance ensures an effective and transparent organization for its different supervisory and operational management teams to create long-term value for all stakeholders. It includes the Management Team and the Board of Directors.

The team focuses on implementing the company’s strategy, overseeing operations, designing action plans, measuring progress, reviewing success in meeting targets, managing change and spearheading the R&D strategy.

The Carmat Board of Directors comprises ten members (including six independent members) who bring a wide array of complementary professional experience to the table. The Board of Directors meets as often as is needed in the interests of the company and at least once every three months, in line with statutory guidelines. Members are appointed for a renewable period of six years.

The Board of Directors determines the strategic, economic, social, financial and scientific focus of Carmat’s activities and ensures that relevant initiatives are implemented.

The committee reviews the preparation and control of financial and accounting information in order to secure the accuracy of information communicated to investors. The committee reviews the conclusions of the works performed by external auditors on the financial information prepared by the company, including the audit of the financial statements and the assessment of internal control.

The Appointments & Compensation Committee comprises two members and is chaired by Dr Philippe Pouletty, representing Truffle Capital.

The committee makes recommendations to the Board of Directors regarding potential appointments to the Management Team, the Board of Directors and key Carmat positions related to company governance. It also sets and reviews compensation policies for executive corporate officers and high-potential employees in line with the company’s targets and individual and collective performance.